Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS ...

As of 9:35:18 AM EST. Market Open.

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.08.

SEC Filings provided by EDGAR Online, Inc.

$ANAB insiders have traded $ANAB stock on the open market 11 times in the past 6 months. Of those trades, 3 have been purchases and 8 have been sales.

Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.